Bookmark

Add to MyYahoo RSS

Cubist Pharmaceuticals News

News on Cubist Pharmaceuticals (Ticker: CBST) continually updated from thousands of sources around the net.

6 hrs ago | JD Supra

The Double Whammy: Cubist's Recent FCPA Disclosure

In the FCPA enforcement world, corporate disclosures of potential violations carrying significant messages.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals, Optimer Pharmaceuticals, Healthcare Law, Law

8 hrs ago | AmericanBankingNews.com

Cubist Pharmaceuticals Director Nancy J. Hutson Sells 9,000 Shares

Cubist Pharmaceuticals Director Nancy J. Hutson sold 9,000 shares of the stock in a transaction dated Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

8 hrs ago | AmericanBankingNews.com

Insider Selling: Cubist Pharmaceuticals COO Unloads 1,003 Shares of Stock

Cubist Pharmaceuticals COO Robert J. Perez sold 1,003 shares of Cubist Pharmaceuticals stock on the open market in a transaction that occurred on Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

11 hrs ago | US Pharmacist

Vancomycin-Resistant Enterococcus

DISCLAIMER: M.P., J.S., N.D., and A.R. are employed by Bouve College of Health Sciences as postdoctoral fellows with Cubist Pharmaceuticals, Inc. ABSTRACT: Vancomycin-resistant Enterococcus is a major cause of hospital-acquired infections in the United States.

Comment?

Related Topix: Biotech, Healthcare Industry, Microbiology, Biology, Science

Mon Aug 18, 2014

AmericanBankingNews.com

Cubist Pharmaceuticals Director Sells $585,000 in Stock

Cubist Pharmaceuticals Director Nancy J. Hutson unloaded 9,000 shares of the company's stock in a transaction dated Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals COO Unloads $63,871 in Stock

Cubist Pharmaceuticals COO Robert J. Perez unloaded 1,003 shares of the stock in a transaction that occurred on Monday, August 18th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

AmericanBankingNews.com

Cubist Pharmaceuticals Stock Rating Lowered by Zacks

They currently have a $58.00 price target on the stock. Zacks 's price objective points to a potential downside of 8.50% from the stock's previous close.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

BioSpace

Cubist Pharmaceuticals, Inc. Could Be An Acquisition Target For Needy Pfizer Inc.

The timing may be right for a takeover of Cubist Pharmaceuticals Inc. The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Thu Aug 14, 2014

Seeking Alpha

Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market?

Cellceutix's Brilacidin flagship one step antibiotic potentially simplifies patient results with a single dose possibly making Brilacidin the physician's first choice for fighting skin infections and oral mucositis.

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, MRSA, Health, Healthcare Law, Law, Food and Drug Administration

Mon Aug 11, 2014

BioSpace

Cubist Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall Of...

Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling nine lots of CUBICINA to the user level following complaints of foreign particulate matter in reconstituted vials.

Comment?

Related Topix: Cubist Pharmaceuticals, Biotech, Medicine, Healthcare Industry

In-PharmaTechnologist.com

CMO issues persist as Cubist announces third recall for potential glass in antibiotic

For the third time since last August, Cubist Pharmaceuticals has recalled lots of its antibiotic Cubicin injection due to the potential of glass particulates in a manufacturing line produced by an unnamed CMO .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Fri Aug 08, 2014

Pharmaceutical Technology

Cubist Pharmaceuticals Recalls CUBICIN

FDA is reporting that Cubist Pharmaceuticals has announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Thu Aug 07, 2014

P&T Community

FDA Approves Orbactiv (Oritavancin) for Skin Infections

The FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin-structure infections caused by susceptible designated Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus .

Comment?

Related Topix: Biotech, Medicines Company The, Medicine, Healthcare Industry, MRSA, Health, Cubist Pharmaceuticals

Wed Aug 06, 2014

Pharmaceutical Processing

Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots of CUBICIN

Cubist Pharmaceuticals today announced it is voluntarily recalling certain lots of CUBICINA to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Freshnews

Cubist Pharmaceuticals Issues Voluntary U.S. Recall of Certain Lots...

Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling certain lots of CUBICIN to the user level due to the potential presence of glass particulate matter in vials produced by a contract manufacturer.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

BioSpace

Cubist Pharmaceuticals, Inc. Recalls Some Vials Of Antibiotic Cubicin

Cubist Pharmaceuticals Issues Voluntary U.S. Recall Of Certain Lots Of CUBICIN 500 Mg In 10 Ml Single Use Vials Due To Presence Of Particulate Matter LEXINGTON, Mass.-- --Cubist Pharmaceuticals, Inc. today announced it is voluntarily recalling certain lots of CUBICINA to the user level due to the potential presence of glass particulate matter in ... (more)

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Reuters

Cubist Pharma recalls some vials of antibiotic Cubicin

Cubist Pharmaceuticals Inc said it recalled some vials of its antibiotic Cubicin due to the potential presence of glass particles.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Aug 05, 2014

Freshnews

Cubist's Once-daily SIVEXTROa (tedizolid phosphate) Available for ...

"We are pleased to formally announce the availability of the I.V. version of SIVEXTRO for physician and hospital order in the U.S.," said Rob Perez, President and Chief Operating Officer of Cubist.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Centers for Disease Control and Prevention, Marketing, MRSA, Health, Infectious Diseases

Sun Aug 03, 2014

AmericanBankingNews.com

Cubist Pharmaceuticals Receives Average Rating of "Buy" from Brokerages

Cubist Pharmaceuticals has been given an average rating of "Buy" by the fourteen brokerages that are currently covering the company, Stock Ratings Network.com reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cubist Pharmaceuticals

Fri Aug 01, 2014

JD Supra

Court Report -- Part III

Cubist Pharmaceuticals Inc. v. Fresenius Kabi USA LLC 1:14-cv-00914; filed July 11, 2014 in the District Court of Delaware Infringement of U.S. Patent Nos.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hispanic Broadcasting, Television, Acorda Therapeutics

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••